Safety and Performance Study of Large Hole Vascular Closure Device

Inclusion Criteria: * Over 18 years of age. * Each patient, or his or her guardian or legal representative, is willing to give informed consent. * Clinically indicated for an endovascular procedure involving access through the femoral artery, with an access puncture of 18 - 24 F. * Females who are not pregnant or lactating, and not planning to become pregnant ≤ 12 months. A pregnancy test may be performed to confirm this. Exclusion Criteria: There will be no exclusion of patients from this trial in respect of race, co-existent disease or concomitant therapy, with the exception of those listed below. * Severe acute non-cardiac systemic disease or terminal illness with a life expectancy of less than one year. * Evidence of systemic bacterial or cutaneous infection, including groin infection. * Evidence of MRSA (Methicillin-resistant Staphylococcus aureus) and/or VRE (vancomycin-resistant Enterococci) colonisation. * With arterial access other than the common femoral artery.\* * Patients suffering with definitive or potential coagulopathy or platelet count less than 100,000/µl. * Patient with a haematocrit of less than 32 %. * A measured activated clotting time (ACT) of greater than 350 seconds immediately prior to sheath removal.\* * If patients are expected to be continuously treated with anticoagulation therapy post-procedure such that their ACT reading is expected to be elevated above 350 seconds for more than 24 hours after the procedure. * Evidence of arterial diameter…